Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels (GLP-1 and GIP), stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors as it is primarily excreted via the biliary/gastrointestinal tract.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients <18 years of age. Use is not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
* **Geriatric:** No dose adjustment required.
## Contraindications
* Hypersensitivity to linagliptin or any component of the formulation.
* History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or sulfonylureas).
* **Serious:** Acute pancreatitis (rare), severe joint pain (arthralgia), bullous pemphigoid, hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin efficacy. If co-administration is necessary, monitor glycemic control closely.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; dose reduction of the secretagogue may be required.
## Monitoring
* **HbA1c:** Typically every 3 to 6 months.
* **Blood Glucose:** Periodic self-monitoring (SMBG).
* **Clinical:** Monitor for signs/symptoms of pancreatitis (persistent severe abdominal pain) and bullous pemphigoid (blistering/erosions).
## Clinical Pearls
* **Excretion:** Linagliptin is the only DPP-4 inhibitor that does not require dose adjustment for renal impairment.
* **Administration:** It can be taken with or without food.
* **Efficacy:** Modest HbA1c reduction (~0.5%–0.7%); weight neutral.
* **Safety:** Does not increase the risk of cardiovascular events or heart failure hospitalizations (unlike some other anti-diabetic agents).
***
**Disclaimer:** This information is for educational purposes only. Clinical practice protocols vary by institution and region. Always verify specific dosing, contraindications, and drug interactions using current, peer-reviewed clinical resources or local prescribing information before initiating therapy.
